By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Affinium Pharmaceuticals 

7000 North Mopac Expwy.
2nd Floor
Austin  Texas  78731  U.S.A.
Phone: 416-645-6614 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical

Segment
Proteomics





Company News
Debiopharm To Acquire Affinium Pharmaceuticals's Antibiotic Clinical Assets And Platform To Identify And Develop Targeted Antibiotics 2/11/2014 9:38:38 AM
Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation By The FDA For AFN-1252 And Completion Of Dosing Of AFN-1720 Phase 1 Trial 11/12/2013 11:51:21 AM
Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round 9/5/2013 9:18:55 AM
Positive Results From Affinium Pharmaceuticals' Phase 2a Clinical Trial of AFN-1252 in ABSSSI 3/21/2013 7:36:16 AM
Affinium Pharmaceuticals Announces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections 8/7/2012 10:36:13 AM
Affinium Pharmaceuticals Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial 5/2/2011 8:45:39 AM
Affinium Pharmaceuticals to Present at Super Bugs - Super Drugs Conference in London, UK 3/15/2011 6:44:34 AM
Affinium Pharmaceuticals Announces the Initiation of a Phase I Clinical Trial Using an Optimized Oral Formulation of AFN-1252, its Novel Anti-staphylococcal Antibiotic 4/12/2010 10:55:19 AM
GlaxoSmithKline (GSK), Novartis AG, Pfizer Inc. (PFE), AstraZeneca AB, Albert Einstein College of Medicine, Centers for Disease Control and Prevention (CDC), And AstraZeneca AB Explore Advances in Anti-Infective Drug Development 12/9/2009 10:35:53 AM
Affinium Pharmaceuticals Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 3/4/2008 8:49:13 AM
12
//-->